Tango Therapeutics (TNGX) Stock Overview
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TNGX Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Tango Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.76 |
| 52 Week High | US$8.80 |
| 52 Week Low | US$1.03 |
| Beta | 1.68 |
| 1 Month Change | 11.82% |
| 3 Month Change | 42.91% |
| 1 Year Change | 11.17% |
| 3 Year Change | 91.60% |
| 5 Year Change | -23.47% |
| Change since IPO | -24.14% |
Recent News & Updates
Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected
Sep 17
US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results
May 15Recent updates
Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected
Sep 17US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results
May 15Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding
Apr 14Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation
Apr 04Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Feb 28Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%
Feb 28Tango Therapeutics: Chance For A Short Squeeze
Jan 23Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?
Dec 05Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 31Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Sep 10What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You
Sep 01Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%
Jun 29Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why
May 30Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06Shareholder Returns
| TNGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.0% | 5.2% | 1.2% |
| 1Y | 11.2% | -0.3% | 17.7% |
Return vs Industry: TNGX exceeded the US Biotechs industry which returned -0.3% over the past year.
Return vs Market: TNGX underperformed the US Market which returned 17.7% over the past year.
Price Volatility
| TNGX volatility | |
|---|---|
| TNGX Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TNGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TNGX's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 155 | Barbara Weber | www.tangotx.com |
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer.
Tango Therapeutics, Inc. Fundamentals Summary
| TNGX fundamental statistics | |
|---|---|
| Market cap | US$863.38m |
| Earnings (TTM) | -US$145.57m |
| Revenue (TTM) | US$24.30m |
Is TNGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNGX income statement (TTM) | |
|---|---|
| Revenue | US$24.30m |
| Cost of Revenue | US$136.45m |
| Gross Profit | -US$112.15m |
| Other Expenses | US$33.41m |
| Earnings | -US$145.57m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | -461.61% |
| Net Profit Margin | -599.14% |
| Debt/Equity Ratio | 0% |
How did TNGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 18:33 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tango Therapeutics, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |
| Eric Schmidt | Cantor Fitzgerald & Co. |